Meeting
2016 ASCO Annual Meeting
Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.
Authors
Clasina Marieke Venema
University Medical Center Groningen, Groningen, Netherlands
Clasina Marieke Venema , Lemonitsa H. Mammatas , Michel van Kruchten , Giulia Apollonio , Carolina Pia Schroder , Andor W. J. M. Glaudemans , Otto S. Hoekstra , Henk M.W. Verheul , Bert van der Vegt , Erik F. J. De Vries , Elisabeth De Vries , Catharina Wilhelmina Menke , Geke Hospers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT01988324
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11553)
DOI
10.1200/JCO.2016.34.15_suppl.11553
Abstract #
11553
Poster Bd #
250
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2022 ASCO Annual Meeting
Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.
First Author: Natasha Hunter
Poster
2020 ASCO Virtual Scientific Program
Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).
First Author: Kimberly McGregor